EUVIMEDEUVIMED entdecken
Klinische Studie

Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension

Andrew Wang, John A Spertus, Daniel M Wojdyla, Theodore P Abraham, Ester Kim Nilles, Anjali Tiku Owens, Sara Saberi, Sharon Cresci, Amy Sehnert, Neal K Lakdawala

JACC: Heart Failure · 2024-03 · 12 (3) · 567-579

DOI: 10.1016/j.jchf.2023.07.030 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift JACC: Heart Failure, 2024-03. Verfasst von Andrew Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA. Electronic address: a.wang@duke.edu. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Heart Failure, Hypertension, Uracil. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Bristol-Myers Squibb Co.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Hypertension (HTN) is common in patients with hypertrophic cardiomyopathy (HCM), but its effect on the treatment of left ventricular outflow tract (LVOT) obstruction is undefined. Although elevated systolic blood pressure (SBP) may impact dynamic LVOT gradients, its response to cardiac myosin inhibition is unknown. OBJECTIVES: In a post hoc exploratory analysis of the EXPLORER-HCM trial (Clinical Study to Evaluate Mavacamten [MYK-461] in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy), the authors examined the characteristics of patients with obstructive HCM and HTN and the associations between HTN, SBP, and the response to mavacamten treatment of LVOT obstruction. METHODS: Patients were stratified by baseline history of HTN and mean SBP during 30-week treatment with mavacamten or placebo. The study estimated treatment differences and evaluated HTN and SBP groups by treatment interaction. Analysis of covariance was used to model changes in continuous endpoints, and a generalized linear model was used for binary endpoints. RESULTS: HTN was present in 119 of 251 patients (47.4%), including 60 receiving mavacamten and 59 receiving placebo. Patients with HTN vs no HTN were older (63.4 vs 54.0 years; P < 0.001), had higher SBP (134 ± 15.1 mm Hg vs 123 ± 13.8 mm Hg; P < 0.001), more comorbidities, and lower peak oxygen consumption (19 ± 3 vs 20 ± 4 mL/kg/min; P = 0.021). Patients with HTN had similar NYHA functional class (NYHA functional class II, 72% vs 73%), Valsalva LVOT gradients (72 ± 34 mm Hg vs 74 ± 30 mm Hg), Kansas City Cardiomyopathy Questionnaire-Clinical Summary Scores (70.6 ± 18.8 vs 68.9 ± 23.1), and NT pro-B-type natriuretic peptide levels (geometric mean 632 ± 129 pg/mL vs 745 ± 130 pg/mL). Mavacamten-treated patients had improvement in all primary, secondary, and exploratory endpoints regardless of HTN status or mean SBP. CONCLUSIONS: The clinical benefits of mavacamten in symptomatic, obstructive HCM were similar in patients with and without HTN, despite differences in baseline characteristics. (Clinical Study to Evaluate Mavacamten [MYK-461] in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy [EXPLORER-HCM]; NCT03470545).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicHeart FailureHypertensionUracilAdultHumansBenzylamines

Stichwörter der Autor:innen

hypertensionhypertrophic cardiomyopathymavacamtenmyosin inhibitorobstruction

Substanzen

BenzylaminesMYK-461Uracil

Autor:innen und Institutionen

  • Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA. Electronic address: a.wang@duke.edu.
  • Departments of Internal Medicine and Biomedical and Health Informatics, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA.
  • Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
  • Division of Cardiology, Department of Medicine, University of San Francisco School of Medicine, San Francisco, California, USA.
  • Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Division of Cardiovascular Medicine, Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA.

Förderung

  • Bristol-Myers Squibb Co

Zitieren

APA

Wang, A., Spertus, J. A., Wojdyla, D. M., Abraham, T. P., Nilles, E. K., Owens, A. T., Saberi, S., Cresci, S., Sehnert, A., & Lakdawala, N. K. (2024). Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension. JACC: Heart Failure, 12(3), 567-579. https://doi.org/10.1016/j.jchf.2023.07.030

Vancouver

Wang A, Spertus JA, Wojdyla DM, Abraham TP, Nilles EK, Owens AT, et al. Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension. JACC: Heart Failure. 2024;12(3):567-579. doi:10.1016/j.jchf.2023.07.030

BibTeX
@article{Wang2024,
  author = {Wang, Andrew and Spertus, John A and Wojdyla, Daniel M and Abraham, Theodore P and Nilles, Ester Kim and Owens, Anjali Tiku and Saberi, Sara and Cresci, Sharon and Sehnert, Amy and Lakdawala, Neal K},
  title = {Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension},
  journal = {JACC: Heart Failure},
  year = {2024},
  volume = {12},
  number = {3},
  pages = {567--579},
  doi = {10.1016/j.jchf.2023.07.030}
}
Kostenlos starten →